跳至主要内容
临床试验/EUCTR2010-019986-27-IT
EUCTR2010-019986-27-IT进行中(未招募)不适用

Breathing disorders in heart failure: high altitude hypoxia as a model to define diagnostic tools, therapeutic strategies and gender related differences. - ND

ISTITUTO AUXOLOGICO ITALIANO0 个研究点开始时间: 2010年6月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Written informed consent - Patients with symptomatic CHF (NYHA functional class II-III, eitheridiopathic or ischaemic and systolic dysfunction (FE < o = 35%) - Clinically stable condition for > o = 3 months - Optimized CHF pharmacological treatment (all drug classes recommended by recent guidelines for this kind of patients, beta-blockers in particular) and resynchronization therapy whenever needed with preserved spontaneous atrial activity and A-V conduction
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Atrial fibrillation - Non optimized pharmacological treatment - Unstable angina - MI, cerebrovascular accident or TIA within the previous three months - Episode of HF decompensation within the previous three months - haemodynamic instability - Conventional indication for pace-maker therapy for AV blocks higher than 1st degree - Clinically relevant pulmonary disease (FEV1<50%, VC<50%, FEV1/FVC<70%) - Inability to perform exercise test, CPAP or oxygen therapy - Use of sedatives, acetazolamide, theophilline and aminophilline

研究者

相似试验

Breathing disorders in heart failure: high altitude... | 临床试验